SPHS Sophiris Bio Inc.

0.35
-0.02  -6%
Previous Close 0.38
Open 0.38
Price To Book -4.41
Market Cap 12,168,665
Shares 34,472,140
Volume 234,571
Short Ratio
Av. Daily Volume 204,551
Stock charts supplied by TradingView

NewsSee all news

  1. Sophiris Bio Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights

    SAN DIEGO and VANCOUVER, British Columbia, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Sophiris Bio Inc. (NASDAQ:SPHS), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in

  2. Sophiris Bio Announces Completion of $4.0 Million Registered Direct Offering

    SAN DIEGO and VANCOUVER, British Columbia, Aug. 30, 2019 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ:SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin (PRX302), a

  3. Sophiris Bio to Present at the H.C. Wainwright 21st Annual Global Investment Conference

    SAN DIEGO and VANCOUVER, British Columbia, Aug. 30, 2019 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin (PRX302), a

  4. Sophiris Bio Announces $4.0 Million Registered Direct Offering

    SAN DIEGO and VANCOUVER, British Columbia, Aug. 27, 2019 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ:SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin (PRX302), a

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 trial planned. Dependent on funding.
Topsalysin (PRX302)
Localized low to intermediate risk prostate cancer
Phase 3 primary endpoints met - November 2015. Second Phase 3 trial dependent on funding.
Topsalysin (PRX302)
Benign prostatic hyperplasia

Latest News

  1. Sophiris Bio Reports Third Quarter 2019 Financial Results and Recent Corporate Highlights

    SAN DIEGO and VANCOUVER, British Columbia, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Sophiris Bio Inc. (NASDAQ:SPHS), a biopharmaceutical company studying topsalysin (PRX302), a first-in-class, pore-forming protein, in

  2. Sophiris Bio Announces Completion of $4.0 Million Registered Direct Offering

    SAN DIEGO and VANCOUVER, British Columbia, Aug. 30, 2019 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ:SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin (PRX302), a

  3. Sophiris Bio to Present at the H.C. Wainwright 21st Annual Global Investment Conference

    SAN DIEGO and VANCOUVER, British Columbia, Aug. 30, 2019 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ: SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin (PRX302), a

  4. Sophiris Bio Announces $4.0 Million Registered Direct Offering

    SAN DIEGO and VANCOUVER, British Columbia, Aug. 27, 2019 /PRNewswire/ -- Sophiris Bio Inc. (NASDAQ:SPHS) (the "Company" or "Sophiris"), a biopharmaceutical company studying topsalysin (PRX302), a